Regeneron Pharmaceuticals' indicated intrinsic value is reportedly
81% higher than its current share price, suggesting a potential undervaluation of its stock. However, the company also faced a setback when its
multiple myeloma drug was rejected by the FDA, sparking some concerns. Despite the setback, positive analyst comments indicate a bullish outlook on the REGN stock. Investments in REGN shares by
LRI Investments LLC were also noted.
The company's
five-year earnings growth, however, appears to be trailing shareholder returns, provoking questions about the firm's financial health. Amidst this, there have been insider sales worth
USD 26 million, hinting at possible weakness.
Regeneron's collaboration with
Doudna-founded Mammoth on gene editing therapies represents a significant move into innovative areas. However, the company failed to secure FDA approval for its
lymphoma candidate, signalling potential risks in its pipeline progression.
Despite some setbacks, REGN stock showed resilience with strong
Q2 earnings, primarily driven by
Eylea HD and Dupixent sales. Legal troubles and insiders selling shares hint at caution, but several experts maintain a positive outlook on the company's stock.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 22 Dec 2023 08:00:00 GMT to Sun, 25 Aug 2024 12:56:13 GMT -
Rating 6
- Innovation 3
- Information 7
- Rumor -3
